A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
Most Recent Events
- 03 Apr 2025 Planned End Date changed from 1 Dec 2024 to 30 Dec 2025.
- 29 Nov 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2024.
- 01 Dec 2022 Results published in the Oral Oncology